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Muscular dystrophies represent a wide and expanding group in neurological prac-tice characterized by inherited progressive degenerative myopathy with differ-ent patterns of neuromuscular and systemic involvement. Dystrophinopathies represent one of the most important groups both because of their frequence 
and their high index of clinical morbidity associated with different chronic and severe compli-
cations1. Duchenne Muscular Dystrophy (DMD) (MIM #310200) represents the main infancy-
onset muscular dystrophy with global distribution and a X-linked recessive pattern of inheri-
tance involving mutation in DMD gene (Xp21.2-p21.1), generally associated with one or more 
deletions of exons resulting in frameshift1, giving rise to severe cardiac and neuromuscular com-
promise, despite the use of most current therapeutic and multidisciplinary approach2,3.  
The advent of neurogenetics, new diagnostic methods and emerging therapeutic pro-
posals makes extremely necessary the review of the main consolidated topics on DMD, as 
well as making guidelines and the adoption of a Brazilian consensus among experts in neu-
romuscular diseases as a reference for the proper practice of the general neurologist and 
neuropediatrician. The study provided by Araújo et al.,4 presented at this issue of Arquivos de 
Neuro-Psiquiatria represents the most recent attempt of classifying evidence levels and rec-
ommendation degrees for different diagnostic and therapeutic aspects related to DMD using 
a systematic review approach of the current medical literaturesince2010, year of publishing of 
the last international guideline of DMD5,6. 
Authors have proposed as their main results of the consensus: (i) the formal recom-
mendation of genetic testing as the first-line exam to provide diagnosis in suspected cases 
of dystrophinopathies (e.g. looking for DMD exon deletion/duplication by techniques such 
as Multiplex Ligation-dependent Probe Amplification/MLPA or Comparative Genomic 
Hybridizationmicroarray/aCGH, and if necessary next-generation sequencing of DMD gene4,7), 
in such a way that muscle biopsy with immunohistochemistry evaluation, classically used as 
a diagnostic tool by many centers, should be performed in cases in which genetic testing is 
unavailable or in cases with high suspicion index with undetermined or non-definite diagnostic 
criteria by prior genetic testing; (ii) the recommendation of using cortico steroids since the diag-
nosis (e.g. prednisolone, deflazacort, or prednisone), most desirably as early as possible2,4,8; and 
(iii) reaffirm the importance of special caution before the adoption of the new current therapeu-
tic purposes by the using of exon-skipping ( for the most common genetic situations) and read 
through agents(in the case of premature stop codon), since most of the results in the studies of 
such therapies (e.g. Ataluren, Drisapersen, Eteplirsen) still have an unknown impact in the long 
term for patients and most emerged from studies limited to initial clinical phases 1 and 23,4, being 
essential to extend such randomized clinical trials to phase 3 with a large number of patients. 
It is believed that through the results from this consensus clinicians and neuropedia-
tricians can improve their care for patients with dystrophinopathies from the appropri-
ate diagnostic process to the possibility of offering proper drug therapy based on current 
scientific evidence. 
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